National Asset Management Inc. Takes Position in Globus Medical Inc (GMED)

National Asset Management Inc. bought a new stake in shares of Globus Medical Inc (NYSE:GMED) during the 1st quarter, Holdings Channel reports. The firm bought 6,437 shares of the medical device company’s stock, valued at approximately $319,000.

Other institutional investors have also made changes to their positions in the company. Investec Asset Management LTD acquired a new position in shares of Globus Medical during the 4th quarter valued at $64,761,000. Oregon Public Employees Retirement Fund increased its position in shares of Globus Medical by 4,284.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,250,619 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 1,222,096 shares during the period. Norges Bank acquired a new position in shares of Globus Medical during the 4th quarter valued at $43,840,000. Janus Henderson Group PLC increased its position in shares of Globus Medical by 18.5% during the 1st quarter. Janus Henderson Group PLC now owns 3,375,803 shares of the medical device company’s stock valued at $166,798,000 after purchasing an additional 527,049 shares during the period. Finally, Vanguard Group Inc increased its position in shares of Globus Medical by 3.4% during the 3rd quarter. Vanguard Group Inc now owns 6,735,494 shares of the medical device company’s stock valued at $382,306,000 after purchasing an additional 219,780 shares during the period. 66.45% of the stock is currently owned by hedge funds and other institutional investors.

In other news, SVP Kelly Huller sold 3,000 shares of Globus Medical stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $48.59, for a total transaction of $145,770.00. Following the transaction, the senior vice president now owns 12,384 shares in the company, valued at $601,738.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Anthony L. Williams sold 212,082 shares of Globus Medical stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $46.83, for a total value of $9,931,800.06. Following the transaction, the president now owns 89,583 shares in the company, valued at approximately $4,195,171.89. The disclosure for this sale can be found here. Insiders sold a total of 426,852 shares of company stock worth $20,061,774 over the last 90 days. Insiders own 24.97% of the company’s stock.

Shares of NYSE GMED opened at $40.58 on Monday. The firm has a market capitalization of $4.02 billion, a P/E ratio of 24.30, a P/E/G ratio of 2.08 and a beta of 0.79. Globus Medical Inc has a 52-week low of $38.01 and a 52-week high of $57.83.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 2nd. The medical device company reported $0.36 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.41 by ($0.05). The company had revenue of $182.90 million during the quarter, compared to analyst estimates of $186.59 million. Globus Medical had a return on equity of 14.09% and a net margin of 20.81%. The business’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.41 earnings per share. Analysts anticipate that Globus Medical Inc will post 1.72 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on GMED. Wells Fargo & Co cut Globus Medical from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $50.00 to $41.00 in a research report on Friday. Needham & Company LLC reiterated a “buy” rating and set a $52.00 price target (down from $57.00) on shares of Globus Medical in a research report on Friday, May 3rd. Zacks Investment Research upgraded Globus Medical from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a research report on Wednesday, April 24th. Oppenheimer reiterated a “hold” rating on shares of Globus Medical in a research report on Tuesday, March 19th. Finally, ValuEngine cut Globus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, March 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company’s stock. Globus Medical has a consensus rating of “Buy” and an average price target of $54.91.

TRADEMARK VIOLATION WARNING: This piece was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.wkrb13.com/2019/05/27/national-asset-management-inc-takes-position-in-globus-medical-inc-gmed.html.

About Globus Medical

Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches.

Featured Story: How to Profit and Limit Losses With Stop Orders

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical Inc (NYSE:GMED).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.